Company Announcement Copenhagen, Denmark; May 28, 2020 Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the Phase III ANDROMEDA (AMY3001) study of subcutaneous (SC) daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for patients with newly diagnosed light-chain (AL) amyloidosis. The study, conducted by Janssen Biotech, Inc. (Janssen), met the primary endpoint of percentage of patients with hematologic complete response.
publication date: May. 29, 2020 FDA has approved Opdivo and Yervoy (nivolumab + ipilimumab) in combination with two cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer, with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.
Introducing the best in mens grooming for the year. The fourth and final segment in this series is a compilation of trusted head-to-toe treatment services every gentleman should indulge in to look and feel your best.Sometimes its better to leave things to an experts hands
For many years, the standard of care for the first-line treatment of patients with MSI-H colorectal cancer has been the combination of mFOLFOX6 plus bevacizumab.
KENILWORTH, N.J.
New York City, United States Since the COVID-19 infection flare-up in December 2019, the malady has spread to right around 100 nations around the world with the World Health Organization proclaiming it a general wellbeing crisis.
Broadcast Date: June 18, 2020Time: 8:00 am PT, 11:00 am ET, 17:00 CET Cell and Gene therapies continue to evolve in their use for treating human diseases. Cell-based therapies are emerging as a promising strategy for cancer, while AAV vectors have taken center stage as a gene delivery vehicle for potential gene therapy for several human diseases
SHUBHAM AGRAWAL ISP Chair: Rodney Gabriel, MD Department of Anesthesiology ISP TITLE: The Association of Preoperative Smoking with Postoperative Outcomes in Patients Undergoing Total Hip Arthoplasty LAUREN ALDERETTE ISP Chair: Bard Cosman, MD, MPH Department of Surgery ISP TITLE: Follicular occlusion syndrome conditions and fissure-fistulas: a study associating the two among veterans ALPHA ANDERS ISP Chair: Alan Shahtaji, DO Department of Family Medicine & Public Health ISP TITLE: An Investigation into Concussion Education, Prevention, and Protocols in Tijuana High Schools. ERIC ARNOLD ISP Chair: Jennifer Wagman, MD, PhD Department of Family Medicine & Public Health ISP TITLE: HIV Counselors perspectives on integrating an Alcohol and IPV screening and brief intervention into standard post test counseling in Ugandan fising villages NADER BADRI ISP Chair: Cheryl Rock, PhD Department of Family Medicine & Public Health ISP TITLE: Insulin Resistance Improves More in Women than In Men in Association with a Weight Loss Intervention ARJUN BANERJEE ISP Chair: Sheila Gahagan, MD, PhD Department of Pediatrics ISP TITLE: Social determinants of cardiovascular health, neurocognitive function, and education outcomes in Chilean adolescents ALEXANDER BELETSKY ISP Chair: Nikhil Verma, MD Department of Orthopaedic Surgery ISP TITLE: When Do Patients Perceive Clinical Benefits After Knee and Shoulder Sports Surgery? JEFFREY BERNSTEIN ISP Chair: Rick Adam Friedman, MD, PhD Department of Surgery ISP TITLE: Epidemiological Survey of Vestibular Schwannoma in the United States SUDARSHAN BHAT ISP Chair: Sunny Smith, MD Department of Family Medicine & Public Health ISP TITLE: Student Hotspotting: An Interdisciplinary Effort in Engaging Super-utilizers of Emergency Medical Services KRISHNA BOMMAKANTI ISP Chair: Richard Garfein, PhD Department of Family Medicine & Public Health ISP TITLE: Prevalence and Correlates of Smartphone Ownership among Tuberculosis Patients in Three Major U.S
DetailsCategory: DNA RNA and CellsPublished on Tuesday, 26 May 2020 18:08Hits: 337 ATLANTA, GA, USA I May 26, 2020 I Expression Therapeutics has announced that it has received clearance by the United States Food and Drug Administration (FDA) to proceed following review of its Investigational New Drug Application (IND) for clinical testing of its novel lentiviral vector-based gene therapy ET3 for hemophilia A. Hemophilia A is the most common severe congenital bleeding disorder and afflicts approximately 1 in 8,000 people.
Immunotherapy Drug Market:Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024. Increasing geriatric population and adoption of targeted therapies with lesser side effects are major key factor which drives the Immunotherapy Drug Market
Recent Comments